{
  "guideline": {
    "id": "PA166161537",
    "name": "Annotation of CPIC Guideline for voriconazole and CYP2C19",
    "source": "CPIC",
    "version": 38,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166161537",
    "relatedChemicals": [
      {
        "id": "PA10233",
        "name": "voriconazole",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298810",
      "name": "Recommendation PA166298810",
      "population": "pediatrics",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061412,
        "html": "<p>Initiate therapy with recommended standard of care dosing</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298814",
      "name": "Recommendation PA166298814",
      "population": "adults",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061416,
        "html": "<p>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendations based upon data extrapolated from patients with CYP2C19*1/*17 genotype.</p>\n"
      },
      "implications": [
        "CYP2C19: In patients for whom an ultrarapid metabolizer genotype (*17/*17) is identified, the probability of attainment of therapeutic voriconazole concentrations is small with standard dosing"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298818",
      "name": "Recommendation PA166298818",
      "population": "adults",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061420,
        "html": "<p>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298805",
      "name": "Recommendation PA166298805",
      "population": "adults",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061407,
        "html": "<p>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing"
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298809",
      "name": "Recommendation PA166298809",
      "population": "pediatrics",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061411,
        "html": "<p>Initiate therapy with recommended standard of care dosing</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298811",
      "name": "Recommendation PA166298811",
      "population": "pediatrics",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061413,
        "html": "<p>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.</p>\n"
      },
      "implications": [
        "CYP2C19: Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298820",
      "name": "Recommendation PA166298820",
      "population": "adults",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061422,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298815",
      "name": "Recommendation PA166298815",
      "population": "adults",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061417,
        "html": "<p>Initiate therapy with recommended standard of care dosing</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal voriconazole metabolism"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298819",
      "name": "Recommendation PA166298819",
      "population": "adults",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061421,
        "html": "<p>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298806",
      "name": "Recommendation PA166298806",
      "population": "pediatrics",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061408,
        "html": "<p>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible.</p>\n"
      },
      "implications": [
        "CYP2C19: In patients for whom an ultrarapid metabolizer genotype (*17/*17) is identified, the probability of attainment of therapeutic concentrations is small"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298812",
      "name": "Recommendation PA166298812",
      "population": "pediatrics",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061414,
        "html": "<p>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.</p>\n"
      },
      "implications": [
        "CYP2C19: Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298816",
      "name": "Recommendation PA166298816",
      "population": "adults",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061418,
        "html": "<p>Initiate therapy with recommended standard of care dosing</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298807",
      "name": "Recommendation PA166298807",
      "population": "pediatrics",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061409,
        "html": "<p>Initiate therapy with recommended standard of care dosing. Use therapeutic drug monitoring to titrate dose to therapeutic trough concentrations.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring (TDM), and comorbidities. Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible. Meticulous TDM is critical for rapid metabolizers. There is insufficient evidence to distinguish a CYP2C19*1/*17 and *1/*1 pediatric patient due to large variability in trough concentrations.</p>\n"
      },
      "implications": [
        "CYP2C19: In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is variable."
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298813",
      "name": "Recommendation PA166298813",
      "population": "pediatrics",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061415,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298808",
      "name": "Recommendation PA166298808",
      "population": "pediatrics",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061410,
        "html": "<p>Initiate therapy with recommended standard of care dosing</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal voriconazole metabolism"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298817",
      "name": "Recommendation PA166298817",
      "population": "adults",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA10233",
          "name": "voriconazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061419,
        "html": "<p>Initiate therapy with recommended standard of care dosing</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.</p>\n"
      },
      "implications": [
        "CYP2C19: Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "27981572",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.",
      "authors": [
        "Moriyama B",
        "Obeng A Owusu",
        "Barbarino J",
        "Penzak S R",
        "Henning S A",
        "Scott S A",
        "Agúndez Jag",
        "Wingard J R",
        "McLeod H L",
        "Klein T E",
        "Cross S J",
        "Caudle K E",
        "Walsh T J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2017,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474211"
    }
  ],
  "version": "2024-02-29-20-19"
}